Pages that link to "Q33587563"
Jump to navigation
Jump to search
The following pages link to Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial (Q33587563):
Displaying 50 items.
- Novel agents and biomarkers for acute lymphoid leukemia (Q26829775) (← links)
- Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia (Q33414592) (← links)
- Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). (Q33558183) (← links)
- A sequential approach with imatinib, chemotherapy and transplant for adult Ph acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. (Q33822032) (← links)
- Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Q35146312) (← links)
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Q35571035) (← links)
- Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China (Q35888941) (← links)
- Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. (Q36123315) (← links)
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study (Q36201257) (← links)
- Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults (Q36461915) (← links)
- Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Q36811503) (← links)
- New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation (Q37344050) (← links)
- Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Q37552083) (← links)
- UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia (Q37564762) (← links)
- Ph ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease (Q37632798) (← links)
- Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. (Q37662200) (← links)
- Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia (Q37702242) (← links)
- Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q37774915) (← links)
- Modern Therapy of Acute Lymphoblastic Leukemia (Q37827276) (← links)
- The role of allogeneic stem cell transplantation for adult acute lymphoblastic leukemia (Q37844312) (← links)
- Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults (Q37851951) (← links)
- Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q37887580) (← links)
- Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies (Q37905034) (← links)
- Current Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia (Q37957411) (← links)
- Current Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Q37967278) (← links)
- Acute Lymphoblastic Leukemia: Monitoring Minimal Residual Disease as a Therapeutic Principle (Q37979956) (← links)
- The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia (Q37992837) (← links)
- Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options (Q38016343) (← links)
- Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools. (Q38023947) (← links)
- Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission (Q38079288) (← links)
- Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q38087930) (← links)
- Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates (Q38095113) (← links)
- Current and future management of Ph/BCR-ABL positive ALL. (Q38194585) (← links)
- Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus (Q38207017) (← links)
- Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. (Q38327984) (← links)
- The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia (Q38375425) (← links)
- Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party o (Q38866851) (← links)
- Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens (Q39420160) (← links)
- Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia (Q40422304) (← links)
- Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph ALL: a study from the adult ALL WG of the JSHCT. (Q40519372) (← links)
- Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B‐lymphoblastic leukemia in the era of tyrosine kinase inhibitors (Q41299717) (← links)
- Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. (Q41697696) (← links)
- Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia (Q41843107) (← links)
- Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. (Q42096217) (← links)
- Autologous Hematopoietic Stem Cell Transplantation for High-risk Acute Lymphoblastic Leukemia: non-Randomized Study with a maximum Follow-up of more than 22 Years (Q42739686) (← links)
- Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia: when and how. (Q42852351) (← links)
- A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Q42929915) (← links)
- Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Q42938334) (← links)
- Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia (Q43175147) (← links)
- Longer follow-up confirms major improvement in outcome in children and adolescents with Philadelphia chromosome acute lymphoblastic leukaemia treated with continuous imatinib and haematopoietic stem cell transplantation. Results from the Spanish Coo (Q46067392) (← links)